Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical therapy. This article reviews the data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how this treatment should be combined with surgical resection (when possible) to optimize patient outcomes. Although surgical resection remains the mainstay of treatment for these tumors, patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. In these patients the drug should be continued until progression, intolerance, or the patients are rendered resectable. Patients with advanced GIST who are successfully resected after imatinib treatment should be placed back on imatinib postoperatively. Patients who develop generalized progression (progression at 2 or more sites) on imatinib should move to other treatments, such as newer TKIs or other targeted approaches currently under study. Genotyping of the tumor should be considered in all pediatric GISTs and high risk adult GISTs, especially if there is progression on imatinib. Quality of life and the cost/benefit of new therapies are important issues for further study in patients with GIST.

    Original languageEnglish (US)
    Pages (from-to)151-159
    Number of pages9
    JournalOncoTargets and Therapy
    Volume2
    StatePublished - 2009

    Fingerprint

    Neoplasms
    Therapeutics
    Imatinib Mesylate
    Gastrointestinal Stromal Tumors
    Sarcoma
    Protein-Tyrosine Kinases
    Cost-Benefit Analysis
    Gastrointestinal Tract
    Phosphotransferases
    Quality of Life
    Pediatrics
    Recurrence
    Mutation
    Pharmaceutical Preparations

    Keywords

    • Gastrointestinal stromal tumors
    • GIST
    • Imatinib

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology (medical)

    Cite this

    Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs). / Vetto, John.

    In: OncoTargets and Therapy, Vol. 2, 2009, p. 151-159.

    Research output: Contribution to journalArticle

    @article{026f2e8e55274addaef0bf3989f0cd85,
    title = "Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)",
    abstract = "Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical therapy. This article reviews the data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how this treatment should be combined with surgical resection (when possible) to optimize patient outcomes. Although surgical resection remains the mainstay of treatment for these tumors, patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. In these patients the drug should be continued until progression, intolerance, or the patients are rendered resectable. Patients with advanced GIST who are successfully resected after imatinib treatment should be placed back on imatinib postoperatively. Patients who develop generalized progression (progression at 2 or more sites) on imatinib should move to other treatments, such as newer TKIs or other targeted approaches currently under study. Genotyping of the tumor should be considered in all pediatric GISTs and high risk adult GISTs, especially if there is progression on imatinib. Quality of life and the cost/benefit of new therapies are important issues for further study in patients with GIST.",
    keywords = "Gastrointestinal stromal tumors, GIST, Imatinib",
    author = "John Vetto",
    year = "2009",
    language = "English (US)",
    volume = "2",
    pages = "151--159",
    journal = "OncoTargets and Therapy",
    issn = "1178-6930",
    publisher = "Dove Medical Press Ltd.",

    }

    TY - JOUR

    T1 - Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)

    AU - Vetto, John

    PY - 2009

    Y1 - 2009

    N2 - Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical therapy. This article reviews the data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how this treatment should be combined with surgical resection (when possible) to optimize patient outcomes. Although surgical resection remains the mainstay of treatment for these tumors, patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. In these patients the drug should be continued until progression, intolerance, or the patients are rendered resectable. Patients with advanced GIST who are successfully resected after imatinib treatment should be placed back on imatinib postoperatively. Patients who develop generalized progression (progression at 2 or more sites) on imatinib should move to other treatments, such as newer TKIs or other targeted approaches currently under study. Genotyping of the tumor should be considered in all pediatric GISTs and high risk adult GISTs, especially if there is progression on imatinib. Quality of life and the cost/benefit of new therapies are important issues for further study in patients with GIST.

    AB - Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical therapy. This article reviews the data supporting the use of the tyrosine kinase inhibitor (TKI) imatinib in GIST patients, and how this treatment should be combined with surgical resection (when possible) to optimize patient outcomes. Although surgical resection remains the mainstay of treatment for these tumors, patients with resected GISTs have high relapse rates that can be reduced by 1 year of adjuvant imatinib. Data also support the use of imatinib for patients with recurrent or unresectable GIST. In these patients the drug should be continued until progression, intolerance, or the patients are rendered resectable. Patients with advanced GIST who are successfully resected after imatinib treatment should be placed back on imatinib postoperatively. Patients who develop generalized progression (progression at 2 or more sites) on imatinib should move to other treatments, such as newer TKIs or other targeted approaches currently under study. Genotyping of the tumor should be considered in all pediatric GISTs and high risk adult GISTs, especially if there is progression on imatinib. Quality of life and the cost/benefit of new therapies are important issues for further study in patients with GIST.

    KW - Gastrointestinal stromal tumors

    KW - GIST

    KW - Imatinib

    UR - http://www.scopus.com/inward/record.url?scp=77953446464&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77953446464&partnerID=8YFLogxK

    M3 - Article

    AN - SCOPUS:77953446464

    VL - 2

    SP - 151

    EP - 159

    JO - OncoTargets and Therapy

    JF - OncoTargets and Therapy

    SN - 1178-6930

    ER -